Related Experiment Video
Updated: Jul 16, 2026

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors
Published on: September 20, 2016
Real-world genomic profiling of solid tumors: validation and clinical insights from a Brazilian cohort
Thalita Xavier de Souza1, Roberta Cardoso Petroni1, Larissa Barbosa de Lima2
1Hospital Israelita Albert Einstein, São Paulo, SP, Brazil.
Background:
Precision medicine has transformed cancer management by tailoring treatments to the molecular characteristics of a patient's tumor. Comprehensive Genomic Profiling enables the simultaneous analysis of multiple genomic alterations using next-generation sequencing assays, providing detailed molecular profiles of tumors. This approach allows more accurate cancer classification, guides decisions regarding targeted therapies, enhances the precision of treatment strategies, and improves patient outcomes in oncology.
Objective:
In this article, we describe the analytical validation of the Illumina TruSight Oncology 500 (TSO500) assay in a (CAP)-certified clinical laboratory in Brazil and present real-world findings from Comprehensive Genomic Profiling performed on 454 patients with cancer, highlighting the genomic landscape, including novel fusion events.
Methods:
Tumor samples collected between January 2020 and September 2023 were subjected to Comprehensive Genomic Profiling using the TSO500 assay. Library preparation and sequencing (Illumina NextSeq) were performed according to the manufacturer's protocol, followed by bioinformatics processing using an in-house pipeline for alignment, variant calling, and annotation. Variants were classified according to the Variant Interpretation for Cancer Consortium guidelines. Analytical performance metrics, including specificity and positive predictive value, were calculated for assay validation.
Results:
The test demonstrated a specificity of 93.39% and a positive predictive value of 73.36%. Regarding Comprehensive Genomic Profiling, 57.85% of all detected variants were classified as variants of uncertain significance, and 42.15% were oncogenic. Gene fusions, including both novel and canonical events, were detected in 13% of cases.
Conclusion:
The TSO500 assay provides crucial insights into patient genomics, aiding diagnosis, prognosis, and treatment decisions. Demonstrating high levels of accuracy, reproducibility, and sensitivity, the TSO500 advances cancer research to the forefront of molecular technology.
Insights
The Illumina TSO500 assay accurately profiles cancer genomics for precision medicine. Comprehensive Genomic Profiling identified oncogenic variants and gene fusions in 454 patients, aiding treatment decisions.
Area of Science:
- Oncology
- Genomics
- Molecular Diagnostics
Background:
- Precision medicine leverages tumor molecular characteristics for tailored cancer treatment.
- Comprehensive Genomic Profiling (CGP) uses next-generation sequencing for detailed tumor molecular profiles.
- CGP enhances cancer classification, targeted therapy guidance, and patient outcomes.
Purpose of the Study:
- To analytically validate the Illumina TruSight Oncology 500 (TSO500) assay in a clinical laboratory setting.
- To present real-world findings from CGP in 454 cancer patients.
- To highlight the genomic landscape, including novel fusion events.
Main Methods:
- Tumor samples underwent CGP using the TSO500 assay (January 2020-September 2023).
- Standard library preparation, Illumina NextSeq sequencing, and in-house bioinformatics pipeline were employed.
- Analytical performance metrics (specificity, positive predictive value) were calculated.
Main Results:
- The TSO500 assay showed 93.39% specificity and 73.36% positive predictive value.
- Of detected variants, 42.15% were oncogenic, and 57.85% were of uncertain significance.
- Gene fusions were detected in 13% of cases, including novel events.
Conclusions:
- The TSO500 assay provides critical genomic insights for cancer diagnosis, prognosis, and treatment.
- The assay demonstrates high accuracy, reproducibility, and sensitivity.
- TSO500 advances cancer research through molecular technology.
More Related Videos
08:08Quantitative Mass Spectrometric Profiling of Cancer-cell Proteomes Derived From Liquid and Solid Tumors
Published on: February 27, 2015
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
Related Concept Videos
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer-Critical Genes II: Tumor Suppressor Genes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
Cancer Survival Analysis
Genomics